drugset / Trial / NCT02049814

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

NCT02049814

Phase 4 Completed 494 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.

Timeline

Start
2014-05-09
Primary completion
2016-06-01
Completion
2016-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acarbose Unknown 100 mg Oral
Subject Voglibose Small molecule 0.3 mg Oral
Background Metformin Small molecule 1000 mg Oral